Literature DB >> 32294235

Macrophages in the pathophysiology of NAFLD: The role of sex differences.

Stefano Ministrini1, Fabrizio Montecucco2,3, Amirhossein Sahebkar4,5,6, Federico Carbone3,7.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a multifactorial pathological condition, which recognizes a certain sexual dimorphism. Experimental and clinical studies provided evidence for a critical role of macrophages in NAFLD development and progression. Especially, liver-resident macrophages (also known as Kupffer cells) are likely the common final pathway of several pro-steatosic signals. A huge amount of danger-associated molecular patterns recognized by Kupffer cells is provided within the liver by lipid and glucose toxicity. Other pro-inflammatory signals come from surrounding tissues into the portal vein, directly to the liver: they come from dysfunctional adipocytes, adipose tissue macrophages and gut dysbiosis. These complex crosstalks are differently represented across sexes, as sexual hormones control many of these processes. Sexual dimorphism then modulates metabolic and inflammatory cascades driving the liver from a simple steatosis to NAFLD and beyond. Here, metabolic and inflammatory mechanisms underlying NALFD pathophysiology will be updated. A special attention will be paid to describe sex-related differences that could provide insights for patient stratification and more tailored therapeutic approaches.
© 2020 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Kupffer cells; inflammation; macrophages; microbiome; nonalcoholic fatty live disease

Mesh:

Substances:

Year:  2020        PMID: 32294235     DOI: 10.1111/eci.13236

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

Review 1.  Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling.

Authors:  Sara Della Torre
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

2.  Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease.

Authors:  Xiao-Yu Liang; Fen-Fang Hong; Shu-Long Yang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-28       Impact factor: 3.168

3.  Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population.

Authors:  Magda Shaheen; Katrina M Schrode; Deyu Pan; Dulcie Kermah; Vishwajeet Puri; Ali Zarrinpar; David Elisha; Sonia M Najjar; Theodore C Friedman
Journal:  Front Med (Lausanne)       Date:  2021-12-02

4.  Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Qi Xie; Shuqing Gao; Min Lei; Zengning Li
Journal:  Aging (Albany NY)       Date:  2022-02-10       Impact factor: 5.682

5.  Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity.

Authors:  Xuelian Zhou; Xiufu Lin; Jingnan Chen; Jiaqi Pu; Wei Wu; Zhaoyuan Wu; Hu Lin; Ke Huang; Li Zhang; Yangli Dai; Yan Ni; Guanping Dong; Junfen Fu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-31       Impact factor: 6.055

6.  Reversal of obesity development in Ceacam1-/- male mice by bone marrow transplantation or introduction of the human CEACAM1 gene.

Authors:  Zhifang Zhang; Deirdre La Placa; Gabriel Gugiu; Alyssa Thunen; Keith Le; John E Shively
Journal:  Obesity (Silver Spring)       Date:  2022-07       Impact factor: 9.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.